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Abstract
Background: Molecular polymerase chain reaction (PCR) based assays are increasingly used to diagnose viral
respiratory infections and conduct epidemiology studies. Molecular assays have generally been evaluated by
comparing them to conventional direct fluorescent antibody (DFA) or viral culture techniques, with few published
direct comparisons between molecular methods or between institutions. We sought to perform a real-world
comparison of two molecular respiratory viral diagnostic methods between two experienced respiratory virus
research laboratories.
Methods: We tested nasal and throat swab specimens obtained from 225 infants with respiratory illness for 11
common respiratory viruses using both a multiplex assay (Respiratory MultiCode-PLx Assay [RMA]) and individual
real-time RT-PCR (RT-rtPCR).
Results: Both assays detected viruses in more than 70% of specimens, but there was discordance. The RMA assay
detected significantly more human metapneumovirus (HMPV) and respiratory syncytial virus (RSV), while RT-rtPCR
detected significantly more influenza A. We speculated that primer differences accounted for these discrepancies
and redesigned the primers and probes for influenza A in the RMA assay, and for HMPV and RSV in the RT-rtPCR
assay. The tests were then repeated and again compared. The new primers led to improved detection of HMPV
and RSV by RT-rtPCR assay, but the RMA assay remained similar in terms of influenza detection.
Conclusions: Given the absence of a gold standard, clinical and research laboratories should regularly correlate the
results of molecular assays with other PCR based assays, other laboratories, and with standard virologic methods to
ensure consistency and accuracy.

Background
Respiratory viruses are common causes of human disease. Molecular detection techniques have allowed previously known viruses to be more reliably identified and
new viruses to be discovered[1-10]. Molecular techniques such as real-time RT-PCR (RT-rtPCR) can be performed for each individual virus, or they can be
combined into a multiplex RT-rtPCR assay. Other molecular methods that can target a single analyte or multiple viruses use a variety of nucleic acid detection based
strategies, including microarrays[11], mass spectrometry
[12], spectrally distinct bead microarrays[13], capillary
electrophoresis [14], or microsphere flow cytometry[15].

The performance of molecular diagnostic methods,
either RT-rtPCR or multiplex assays, typically has been
evaluated by comparing them with conventional direct
fluorescent antibody (DFA) or culture, with few direct
comparisons reported between molecular assays. Moreover, there are few reports of laboratories collaboratively
comparing methods between institutions. In this study,
we compared a multiplex respiratory virus panel
(Respiratory MultiCode Assay [RMA], EraGen Biosciences and U. Wisconsin-Madison) with RT-rtPCR
(Vanderbilt University) for the detection of 11 common
respiratory viruses.

Methods
* Correspondence: john.williams@vanderbilt.edu
1
Department of Pediatrics, Vanderbilt University School of Medicine, 1161
21st Avenue South, Nashville, TN, 37232, USA
Full list of author information is available at the end of the article

Clinical specimens

Nasal and throat swabs were collected from children ≤
12 months old who were admitted to the Monroe Carell
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Jr. Children’s Hospital at Vanderbilt from September 1,
2005 through May 31, 2006 with acute respiratory illness, as part of the Tennessee Children’s Respiratory
Initiative [16]. All specimens collected during this period
were included in the study. Within four hours of collection, the samples were divided into aliquots, lysis buffer
added, and specimens were frozen at -80°C. Separate
unthawed aliquots were sent to the research laboratories
at Vanderbilt University and University of WisconsinMadison for RT-rtPCR and RMA testing, respectively.
Real-time RT-PCR testing

Single RT-rtPCR experiments were performed for the
following 11 viruses: respiratory syncytial virus (RSV),
influenza A and B, human metapneumovirus (HMPV),
human rhinovirus (HRV), parainfluenza 1, 2 and 3
(PIV1, PIV2, PIV3), and human coronaviruses Netherlands (NL-63), OC43, and 229E. RNA was extracted on
an automated instrument (MagNApure Total Nucleic
Acid extraction kit; Roche Applied Science), and refrozen at -80°C until each individual RT-rtPCR was performed. Primers and probes for HCoV-NL63, OC43,
229E, RSV, HMPV and HRV were obtained from the
published literature[17-22]. Influenza primer and probe
sequences were provided by Steve Lindstrom, Centers
for Disease Control and Prevention [23]. Primers and
probes for PIV1, 2 and 3 were designed using Primer
Express version 2.0 (Applied Biosystems). Primer and
probe sequences, concentration, and annealing temperatures are listed in Table 1. Twenty-five-μL reaction mixtures containing 5 μL of specimen RNA were tested
using the QuantiTect Probe RT-PCR kit (QIAGEN) on
a Smart Cycler II (Cepheid). Cycling conditions were 30
min at 50°C, 15 min at 94°C, and 45 cycles of 8 seconds
at 94°C and 60 seconds at 55-66°C (Table 1). All RTrtPCR assays were optimized and characterized using
RNA runoff transcripts and were capable of detecting <
50 RNA transcript copies/reaction (data not shown). All
samples were tested by a commercial RT-rtPCR assay
for human beta-actin mRNA (Applied Biosystems) to
ensure RNA integrity.
RMA

RMA is a multitarget, high throughput technology that
integrates multiplex PCR and microsphere flow cytometry [15,24,25]. While the Luminex technology can detect
up to 80 targets in one reaction, this version of the
assay included 19 viral targets. We report results for the
same 11 viruses tested by the RT-rtPCR assays. Nucleic
acid was extracted with Trizol reagents. The RMA assay
was performed with primers and conditions as previously described, including the addition of an external
insect virus spiked into each specimen to control for
RNA extraction, RT, and PCR [15].
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Retesting with RT-rtPCR and RMA

Both sites were blinded to the results from the other
laboratory until all data were analyzed. In order to
address potential weaknesses indicated by discordant
results between the two assays in the first round of
comparison, both RT-rtPCR and RMA testing were
modified for a second round of testing. The first round
primers and probes for RSV and HMPV [19,21] were
changed for the RT-rtPCR assay[18] and (Klemenc et al,
unpublished data) and all samples were retested for
these two viruses. In the RMA assay, the primers and
probe for influenza A were modified and the cDNA
synthesis protocol was changed from Promega reagents
to the Applied Biosystems High-Capacity cDNA Kit.
Statistical Analysis

Demographic and clinical variables of the study sample
are described as frequencies and percent or median and
interquartile ranges [IQR] as appropriate. The RMA and
RT-rtPCR assays were compared using the test for
inter-rater agreement (kappa coefficient). Kappa coefficient was calculated for any comparison in which the
value of all data cells was ≥ 3, with a kappa ≥ 0.75 considered to indicate good agreement. Bootstrapping was
used to estimate 95% confidence limits of kappa. Cycle
threshold (Ct) numbers for influenza and RSV were
compared between groups of specimens using the t-test.

Results
A total of 225 infants hospitalized with respiratory
symptoms were enrolled from September 2005 through
May 2006. Samples from 222 children were available for
study in both sites; three specimens were only available
for RMA testing. Study children were 57% male with a
median age of 13 weeks [IQR 7-33 weeks]. The admitting diagnoses of these infants were bronchiolitis (58%),
upper respiratory infection (33%), and other (9%).
Rates of viral detection were compared using both
assay methods. Restricting the analysis to the 11 viruses
tested with both methods, at least one virus was
detected in 174 (78.3%) samples by RMA and in 163
(73.4%) samples by RT-rtPCR. A total of 194 and 196
viruses were identified in these samples by RMA and
RT-rtPCR, respectively (Table 2).
RSV

In the first round of testing, RMA detected more RSV
(n = 98, 44%) than RT-rtPCR (n = 78, 35%). The kappa
coefficient between the two tests was 0.66. RMA also
differentiated between RSV sub-types A and B. Of the
RSV positive samples detected by RMA, 67 were RSV A
and 32 were RSV B (one sample had both RSV A and
RSV B). Of the 67 RSV A identified through RMA, RTrtPCR detected RSV in 65 (97%) of them. However, of

Forward primer

μM

HRV (5’ UTR)$

CY+AGCC+TGCGTGGC

0.8

GAAACACGGACACCCAAAGTA

1st Round RSV (M)

GGAAACATACGTGAACAAGCTTCA

1

A: CATCGTCTTTTTCTAAGACATTGTATTGA
B: TCATCATCTTTTTCTAGAACATTGTACTGA

0.5

Virus (target)

Reverse primer

μM

Probe (5’ to 3’)

μM

°C

Ref

0.8

TCCTCCGGCCCCTGAATGYGGC

0.1

60

[20]

0.5

TGTGTATGTGGAGCCTTCGTGAAGCAAG

0.2

60

[19]

2nd Round RSV (M)

GGCAAATATGGAAACATACGTGAA

1

TCTTTTTCTAGGACATTGTAYTGAACAG

1

CTGTGTATGTGGAGCCTTCGTGAAGCT

0.2

60

[18]

1st Round HMPV (N)

CATATAAGCATGCTATATTAAAAGAGTCTC

1

CCTATTTCTGCAGCATATTTGTAATCAG

1

TGYAATGATGAGGGTGTCACTGCGGTTG

0.2

60

[21]

2nd Round HMPV (N)

CATAYAARCATGCTATATTAAAAGAGTCTC

1

CCTATYTCWGCAGCATATTTGTAATCAG

1

CAACHGCAGTRACACCYTCATCATTRCA

0.2

60

*

HCoV OC43 (N)

CGATGAGGCTATTCCGACTAGGT

1

CCTTCCTGAGCCTTCAATATAGTAACC

1

TCCGCCTGGCACGGTACTCCCT

0.5

60

[22]

HCoV 229E (N)

CAGTCAAATGGGCTGATGCA

1

AAAGGGCTATAAAGAGAATAAGGTATTCT

1

CCCTGACGACCACGTTGTGGTTCA

0.5

60

HCoV-NL (N)

AGGACCTTAAATTCAGACAACGTTCT

1

GATTACGTTTGCGATTACCAAGACT

1

TAACAGTTTTAGCACCTTCCTTAGCAACCCAAACA

0.5

66

[17]

PIV 1 (N)

GGATATCCTGCATGTCTCGG

1.5

GGCACTTTTAACGGTTCCATC

1.5

CCATAACAAGTAGTGCTGGTCTAAGAAAAGGATTCTTC

0.2

60

*

PIV 2 (N)

CACTTAAATATGGACTTGGAACAAGATG

1.5

TCCATCAGYTTTGGTGATTCTAATAGAG

1.5

CTACATTATCAGAGTCTAGGACCCATGGCCAA

0.2

60

*

PIV 3 (N)

AGCCATGCAACAGTATGTGACG

1.5

TTRGMTTCGTGTGTCACTCCAAGTTC

1.5

ATYTGAGCTTCRGCATCACGTGCTACTG

0.2

60

*

Flu A (M)

GACCRATCCTGTCACCTCTGAC

0.8

AGGGCATTYTGGACAAAKCGTCTA

0.8

TGCAGTCCTCGCTCACTGGGCACG

0.2

55

§

Flu B (NS)

TCCTCAACTCACTCTTCGAGCG

0.8

CGGTGCTCTTGACCAAATTGG

0.8

CCAATTCGAGCAGCTGAAACTGCGGTG

0.2

55

§

Ali et al. Virology Journal 2011, 8:332
http://www.virologyj.com/content/8/1/332

Table 1 Primer and probe sequences, reaction concentrations, and annealing temperatures used for RT-rtPCR assays.

$ HRV forward primer: + = LNA base.
* this manuscript
§ CDC protocol (World Health Organization. CDC Protocol of Realtime RTPCR for Swine Influenza A (H1N1). April 28, 2009. http://www.who.int/csr/resources/publications/swineflu/
CDCrealtimeRTPCRprotocol_20090428.pdf).
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Table 2 Comparison of RMA and RT-rtPCR assays
RMA (1)*
Virus
RSV

HRV

HMPV

Influenza
A

PIV 1

PIV 2

RT-rtPCR (1) Positive Negative Total
**
Positive

70

8

Negative

28

116

Positive

50

13

Negative

6

153

Positive

2

0

Negative

6

214

Positive

4

21

Negative

3

194

Positive

9

4

Negative

1

208

Positive

1

0

Negative

0

221

Positive

5

1

Negative

3

211

Kappa
(95%CI)†

222

0.66 (0.56-0.76)

222

0.78 (0.68-0.87)

detected by the RMA assay, the repeat sample analysis
detected RSV in 66 and 28 respectively. 12 samples
were positive for RSV with repeat RT-rtPCR testing but
negative for RSV with RMA testing; the mean Ct for
these specimens was higher than the mean Ct for specimens detected by both assays (34.54 ± 3.18 vs. 28.58 ±
3.71, p < 0.001).
Influenza

In the first round, the RT-rtPCR detected influenza A in
25 (11.2%) samples while the RMA detected influenza A
in 7 (3.1%) samples. RT-rtPCR detected influenza B in 1
sample while RMA detected influenza B in a different
sample. In the second round of testing, the influenza A
RMA primers and probes were redesigned. Compared
to 25 samples positive for influenza A by rRT-PCR, the
repeat RMA assay detected 5 positive samples; all 5
were also detected by the RT-rtPCR assay. The mean Ct
of the 5 influenza A specimens detected by the RMA
assay was lower than the mean Ct of all influenza A
specimens (30.02 ± 1.98 vs. 34.99 ± 1.88, p < 0.001).

222

222

222

222

Human rhinovirus
CoV NL63

CoV OC43

Positive

4

1

Negative

0

215

RT-rtPCR detected HRV in 63 (28.2%) samples as compared to the RMA, which detected HRV in 56 (25.1%)
samples (kappa coefficient 0.78). In two of the discordant samples, RT-rtPCR detected HRV while the RMA
detected enterovirus.

220

220

RT-rtPCR (2)
RSV

HMPV

Positive

95

12

Negative

3

110

Positive

4

1

Negative

2

211

0.86 (0.78-0.92)
220

218

RMA (2)
Influenza
A

RT-rtPCR (1)

Positive

Negative

Positive

5

20

Negative

0

196

222

*Kappa for agreement assessments is reported when all cells are ≥ 3.
RSV = respiratory syncytial virus, HRV = human rhinovirus, HMPV = human
metapneumovirus, PIV = parainfluenza virus, CoV = coronavirus.
RMA (1) = first RMA run, RMA (2) = second RMA run with revised primers/
probes, RT-rtPCR (1) = first RT-rtPCR run, RT-rtPCR (2) = second RT-rtPCR run
with revised primers/probes.

the 42 RSV B detected by RMA, RT-rtPCR only
detected RSV B in 6 (14.2%) samples.
In the second round, the primers and probes for the
RSV RT-rtPCR assay were redesigned based on further
analysis of published viral sequences [18]. Using these
new primers and probes, RSV was identified in 107
(49%) samples with RT-rtPCR. The inter rater agreement for RSV between the repeat RT-rtPCR and the
first RMA was 0.86. Of the 67 RSV A and 32 RSV B

Human metapneumovirus

During the first round of testing, RMA detected HMPV
in 8 (3.5%) samples while RT-rtPCR detected HMPV in
2 (0.9%) samples. In the second round using redesigned
RT-rtPCR HMPV primers and probes, HMPV was
detected in 7 samples, 5 of which were concordant with
the results of the first RMA assay. The first RMA assay
detected HMPV in 2 additional samples that were not
detected by the repeat RT-rtPCR assay, while one sample positive for HMPV in the first RMA was negative in
the second set of tests.
Human coronaviruses

NL63 was detected in 8 (3.5%) samples through RMA
and in 6 (2.7%) samples through RT-rtPCR. HCoV
OC43 was detected in 5 (2.2%) samples through RMA
and in 5 (2.3%) samples through RT-rtPCR. HCoV 229E
was not detected in any sample by either assay.
Parainfluenza viruses

PIV1 was detected in 10 (4.4%) samples through RMA
and in 13 (5.8%) samples through RT-rtPCR. PIV 2 was
detected in 1 (0.5%) sample through RMA and in 1
(0.5%) sample through RT-rtPCR. No PIV3 was detected
by either method.
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Test/retest of respiratory viruses using the RMA assay

The comparison of the first and second run of RMA
assay is summarized in Table 2. The most notable discrepancies between runs were for HRV and RSV.

Discussion
The sensitivity and specificity of multiplex viral diagnostic
assays have generally been compared to viral culture and
DFA[1], instead of more sensitive RT-rtPCR methods
[2,26-28]. Comparison of molecular methods with other
sensitive molecular techniques, such as RMA with RTrtPCR, is appropriate to determine whether the sensitivity
for each analyte is sufficient for clinical or research use.
Although both assays performed well for selected viruses
in this study, the first round of comparison revealed differences in the rates of detection for specific viruses (Table
2). The RMA assay detected significantly more HMPV
and RSV, while the RT-rtPCR assay detected more influenza A and HRV. Redesigning primers led to substantial
improvements in the detection of HMPV and RSV by
rRT-PCR, while there was little improvement in the performance of RMA for influenza virus with the change in
primers. This discordance could have been due to
sequence variation; there was insufficient residual specimen to sequence the viruses. However, both influenza A
assays targeted regions of the matrix gene that are highly
conserved among GenBank sequences (data not shown).
The mean Ct of the influenza and RSV specimens
detected only by the RT-rtPCR assay was significantly
higher than those detected by the RMA assay, suggesting
that the discordance may have been due to the sensitivity
of the two assays for specimens with a lower viral load.
One recent study compared a commercial version of
the RMA known as PLx-Respiratory Viral Assay (PLxRVP) to RT-rtPCR and found good concordance, but
only tested a portion of the PLx-RVP negative samples
[29]. The RMA and PLx-RVP differ both in primer
sequences, and in the method used to extract RNA and
perform reverse transcription. Both of these factors are
important determinants of assay sensitivity. Given that
RNA viruses are prone to mutation[30], currently circulating field strains of these viruses should be regularly
monitored for sequence divergences that would affect
primers and probes used in PCR-based assays. This is
particularly true for influenza, which undergoes considerable variation every year. Molecular assays are often
targeted to conserved internal genes, but this is based
on known sequences. Further, due to segment reassortment and antigenic shift, new internal gene segments
may arise among influenza viruses infecting humans.
For multiplex assays such as the RMA, inclusion of two
probe sets that target two different parts of the viral
genome might eliminate the risk that a single mutation
would lead to nondetection.
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Our study has some limitations. First, we did not use
identical extraction methods and primers in the RTrtPCR and RMA assays, and therefore discrepant results
could have been due to differences in these processes or
primer design. However, this was an intentional choice,
since the specific goal of this study was to compare two
“real-world” methods. Both laboratories have published
extensively in the area of respiratory virus diagnostics
and epidemiology, and have evaluated their independent
methods. This study shows that collaboration between
groups offers a valuable tool to assess assay performance
impartially. Second, we did not use a gold standard test
to confirm presence or absence of virus in cases of discrepancy between the two assays. We explored the
option of sequencing of the discordant samples to detect
sequence differences or false positives, but there was not
enough residual specimen to allow this. Nonetheless, we
repeated the testing of viruses that had major discrepancies with the assumption that if the repeats were positive, it provided reassurance that the positive samples
were true positives. Third, the RT-rtPCR was only
repeated for HMPV and RSV due to limited sample;
there could have been discordances for other viruses.
Fourth, the RMA assay was repeated with altered influenza primers while other primers were unchanged; it is
possible that a change in influenza primers had an
impact on the overall performance of the assay. One
important consideration for any multiplex assay is the
need to re-optimize for all targets when a change is
made in any of the primers used. Finally, the results
were not evaluated by DFA or culture, though the
objective was to directly compare sequence-based
methods.
In summary, for most viruses tested, there was good
agreement between the two assays. However, discrepancies highlight the need for similar comparisons between
molecular assays on a routine basis, so that weaknesses
can be promptly identified and corrected. While investigators may be reluctant to make comparisons that
might suggest deficiencies of particular methods, collaborative studies such as ours are critical to advance
these diagnostic methodologies. Two other recent studies comparing molecular methods identified similar
discrepancies [29,31]. In addition to clinical specimens
validated by culture, respiratory virus proficiency panels
distributed by quality control programs like the European Quality Control for Molecular Diagnostics
(QCMD) [32], CDC, or College of American Pathologists, or commercial proficiency panels (e.g., ZeptoMetrix NATtrol™ Respiratory Validation Panels) provide
an external quality control. Clearly, the overall comparison between molecular methods should consider the
performance of each individual analyte. The goal of this
study was not to determine which is the “best” assay;
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the choice of assay for a given purpose depends on
many factors, including cost, available equipment and
expertise, sample volume, and others. Multiplex assays
may offer substantial savings in time and cost due to
multiple analytes, and are generally preferred for clinical
testing. Comparison of molecular diagnostic methods to
culture and DFA is useful to establish validity, and
ensure that cultivable viruses are correctly identified by
sequence-based technology. However, our data show
that molecular diagnostic methods also must be compared to other molecular techniques to assess performance, particularly because of the superior sensitivity of
the molecular methods compared to culture and DFA.
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